Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New hope for elderly lung cancer patients: combined surgery and rehab study launches

NCT ID NCT07632664

Disease control Sponsor: Peking University People's Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 25, 2026 · Last updated Jul 16, 2026 · Updated 3 times

Summary

This study is testing a new treatment model for elderly patients (65+) with early-stage lung cancer. It combines advanced surgical techniques, personalized care before and after surgery, and rehabilitation programs. The goal is to improve survival and reduce complications. Researchers will enroll 1,000 participants across multiple centers in China.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Surgery (lobectomy or segmentectomy) plus perioperative care and rehabilitation
What this could lead to
If successful, this could establish a safer, more effective treatment pathway for elderly lung cancer patients, potentially improving survival and quality of life.
What could go wrong
This is an early-stage study without a control group, so results may not prove the new model is better than standard care. Risks include surgical complications and the challenges of treating older patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 1,000 people

The number the study aims to enrol. It can still change while the study runs.

Started

Aug 2024

Expected to finish

Aug 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

65 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Aged ≥65 years old 2. Pathologically confirmed non-small cell lung cancer with clinical stage eligible for curative surgical resection 3. Complete preoperative geriatric comprehensive assessment data available 4. Capable of finishing planned surgery and long-term follow-up 5. Voluntarily sign informed consent form Exclusion Criteria: 1. History of other malignant tumors within recent 5 years 2. Severe organic dysfunction of heart, liver, renal or respiratory system that cannot tolerate thoracic surgery 3. Preoperative confirmed distant metastasis preventing radical resection 4. Uncontrolled active severe infection or obvious coagulation disorders 5. Severe psychiatric disorder or cognitive dysfunction failing to cooperate with treatment and follow-up 6. Refuse random grouping and postoperative regular monitoring

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Aged are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

lung neoplasm non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Aged Lung neoplasm Perioperative care Postoperative rehabilitation Thoracic surgical procedures

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Peking University People's Hospital

    RECRUITING

    Beijing, Beijing Municipality, 100044, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.